Ultragenyx Pharmaceutical(RARE.US) Officer Sells US$441.27K in Common Stock

$Ultragenyx Pharmaceutical(RARE.US)$ Officer Parschauer Karah Herdman sold 9,806 shares of common stock on Jun 12, 2024 at an average price of $45 for a total value of $441.27K.Source: Announcement Wh

moomoo News20:30 ET

Form 144 | Ultragenyx Pharmaceutical(RARE.US) Officer Proposes to Sell 441.27K in Common Stocks

SEC FILLINGS DISCLOSED/ Jun 12, $Ultragenyx Pharmaceutical(RARE.US)$ Officer KARAH PARSCHAUER intends to sell 9,806 shares of its common stock on Jun 12, with a total market value of approximately $44

moomoo News17:13 ET

Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025

Ultragenyx Pharmaceutical (RARE) said Wednesday it intends to file late this year or early next year a biologics license application with the US Food and Drug Administration for the accelerated approv

MT Newswires16:50 ET

Express News | Ultragenyx - Agreement Reached With FDA That Csf Heparan Sulfate (Hs) Can Be Used as a Reasonable Surrogate Endpoint for Accelerated Approval

Reuters16:22 ET

Ultragenyx Pharmaceuticals to Seek Accelerated Approval of Genetic Disease Treatment

By Ben Glickman Ultragenyx Pharmaceuticals said it will seek accelerated approval of its treatment for Sanfilippo syndrome after regulators approved the company's surrogate endpoint. The Novato, Cal

WSJ16:11 ET

Express News | Ultragenyx Shares Are Trading Lower After the Company Announced a Proposed Public Offering of Common Stock and Pre-funded Warrants

Benzinga16:09 ET